FI66867C - Foerfarande foer framstaellning av nya farmakologiskt aktiva 3-alkylxantiner - Google Patents

Foerfarande foer framstaellning av nya farmakologiskt aktiva 3-alkylxantiner Download PDF

Info

Publication number
FI66867C
FI66867C FI793224A FI793224A FI66867C FI 66867 C FI66867 C FI 66867C FI 793224 A FI793224 A FI 793224A FI 793224 A FI793224 A FI 793224A FI 66867 C FI66867 C FI 66867C
Authority
FI
Finland
Prior art keywords
methyl
preparation
pyrimidinedione
dione
purine
Prior art date
Application number
FI793224A
Other languages
English (en)
Finnish (fi)
Other versions
FI793224A (fi
FI66867B (fi
Inventor
Per Gunnar Kjellin
Carl Goeran August Persson
Original Assignee
Draco Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Draco Ab filed Critical Draco Ab
Publication of FI793224A publication Critical patent/FI793224A/fi
Application granted granted Critical
Publication of FI66867B publication Critical patent/FI66867B/fi
Publication of FI66867C publication Critical patent/FI66867C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI793224A 1978-10-20 1979-10-17 Foerfarande foer framstaellning av nya farmakologiskt aktiva 3-alkylxantiner FI66867C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE7810947A SE7810947L (sv) 1978-10-20 1978-10-20 3-alkylxanthines
SE7810947 1978-10-20

Publications (3)

Publication Number Publication Date
FI793224A FI793224A (fi) 1980-04-21
FI66867B FI66867B (fi) 1984-08-31
FI66867C true FI66867C (fi) 1984-12-10

Family

ID=20336145

Family Applications (1)

Application Number Title Priority Date Filing Date
FI793224A FI66867C (fi) 1978-10-20 1979-10-17 Foerfarande foer framstaellning av nya farmakologiskt aktiva 3-alkylxantiner

Country Status (24)

Country Link
US (2) US4548818A (fr)
EP (1) EP0010531B1 (fr)
JP (1) JPS5557589A (fr)
AT (1) ATE1145T1 (fr)
AU (1) AU530717B2 (fr)
CA (1) CA1131632A (fr)
DD (1) DD146708A5 (fr)
DE (1) DE2963021D1 (fr)
DK (1) DK148884C (fr)
ES (1) ES485178A1 (fr)
FI (1) FI66867C (fr)
GR (1) GR72945B (fr)
HK (1) HK7785A (fr)
HU (1) HU180220B (fr)
IE (1) IE49184B1 (fr)
NO (1) NO152561C (fr)
NZ (1) NZ191870A (fr)
PH (1) PH16676A (fr)
PL (1) PL119413B1 (fr)
PT (1) PT70350A (fr)
SE (1) SE7810947L (fr)
SG (1) SG86084G (fr)
SU (1) SU952105A3 (fr)
ZA (1) ZA795113B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
SE8002910L (sv) * 1980-04-18 1981-10-19 Draco Ab 3,8-dialkylxantiner, forfarande for deras framstellning, beredning och metoder for behandling av kronisk obstruktiv luftvegssjukdom och kardiovaskulera sjukdomar
CH643260A5 (fr) * 1980-05-02 1984-05-30 Nestle Sa 1-allyl-3-butyl-8-methylxanthine, procede de preparation et utilisation dans un medicament.
IT1200944B (it) * 1982-08-10 1989-01-27 Malesci Sas Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
US5338741A (en) * 1986-10-27 1994-08-16 Nestec S.A. 1-hydroxyalkylxanthines and medicaments containing them
IL92096A0 (en) 1988-10-25 1990-07-12 Abbott Lab Carboxylic nucleoside analogs
US5153352A (en) * 1988-10-25 1992-10-06 Bristol-Myers Squibb Company Process for preparation of intermediates of carbocyclic nucleoside analogs
US5246931A (en) * 1988-10-25 1993-09-21 Bristol-Myers Squibb Company Carbocyclic nucleoside analogs
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
US4988703A (en) * 1989-05-22 1991-01-29 Abbott Laboratories Carbocyclic nucleoside analogs with antiviral activity
CA2030112A1 (fr) * 1989-11-24 1991-05-25 Yasuo Ito Compose de xanthine, methode de preparation et composition pharmaceutique contenant ledit compose
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
DK0502690T3 (da) * 1991-03-05 2000-05-22 Ajinomoto Kk Cyclopropanderivat
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
WO2000002861A1 (fr) 1998-07-10 2000-01-20 The United States Of America, Represented By Secretary, Department Of Health And Human Services Antagonistes du recepteur de l'adenosine a¿3?
ATE336492T1 (de) * 2000-01-14 2006-09-15 Us Gov Health & Human Serv Methonocarbacycloalkylanaloga von nucleosiden
US6623553B2 (en) * 2001-04-20 2003-09-23 John Russell Printing process with edible inks
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
WO2004074247A2 (fr) * 2003-02-19 2004-09-02 Endacea, Inc. Antagonistes du recepteur de l'adenosine a1
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
CA2528367A1 (fr) * 2003-06-09 2004-12-23 Endacea, Inc. Antagonistes de recepteur d'adenosine a1
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
DE102006020519A1 (de) * 2006-05-03 2007-11-08 Robert Bosch Gmbh Vorrichtung zum Einfalten zumindest einer Lasche einer Verpackung
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US7743683B2 (en) * 2006-08-15 2010-06-29 Umagination Labs, L.P. Systems and methods of a power tool system with interchangeable functional attachments powered by a direct rotational drive
US8518957B2 (en) 2009-12-02 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure
EP3397640B1 (fr) * 2015-12-29 2021-08-04 INSERM - Institut National de la Santé et de la Recherche Médicale Inhibiteurs de protéines bet dérivés de la xanthine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
DE864868C (de) * 1943-10-02 1953-01-29 Hellmut Dr Bredereck Verfahren zur Herstellung von Purinverbindungen
US2646432A (en) * 1947-01-13 1953-07-21 Mallinckrodt Chemical Works Method of preparing 2, 6-diketopurines
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
GB683523A (en) * 1948-08-18 1952-12-03 Beecham Res Lab The manufacture of purine derivatives
US2781344A (en) * 1953-05-04 1957-02-12 Monsanto Chemicals Formylation of amino-pyrimidines
US2844576A (en) * 1955-11-22 1958-07-22 American Cyanamid Co Preparation of purines
BE592753A (fr) * 1959-07-09 1900-01-01
GB982079A (en) * 1962-05-01 1965-02-03 Dresden Arzneimittel Process for the production of xanthine derivatives
GB1008454A (en) * 1963-03-26 1965-10-27 Dresden Arzneimittel Pseudoxanthines
JPS53890B2 (fr) * 1972-04-22 1978-01-12
GB1435916A (en) * 1972-05-11 1976-05-19 Beecham Group Ltd Pharmaceutical weight-reducing compositions
JPS5125009U (fr) * 1974-08-14 1976-02-24
FR2346244A1 (fr) * 1976-03-30 1977-10-28 Chamagne Pierre Nouveau conditionnement pour la conservation de liquides alimentaires
CA1077932A (fr) * 1976-03-31 1980-05-20 Berlex Laboratories, Inc. Composes de la xanthine pour le traitement des bronchospasmes et des affections allergiques
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
JPS52133295U (fr) * 1976-04-05 1977-10-11
JPS5618169Y2 (fr) * 1976-09-20 1981-04-28
SE416810C (sv) * 1977-10-14 1982-07-19 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
US4338319A (en) * 1979-11-27 1982-07-06 Aktiebolaget Draco Method for the treatment of chronic obstructive airway or cardiac diseases
SE8002910L (sv) * 1980-04-18 1981-10-19 Draco Ab 3,8-dialkylxantiner, forfarande for deras framstellning, beredning och metoder for behandling av kronisk obstruktiv luftvegssjukdom och kardiovaskulera sjukdomar

Also Published As

Publication number Publication date
PL219065A1 (fr) 1980-06-16
NO152561B (no) 1985-07-08
NZ191870A (en) 1984-07-06
EP0010531B1 (fr) 1982-06-02
HU180220B (en) 1983-02-28
US4644001A (en) 1987-02-17
AU5187179A (en) 1980-05-01
SU952105A3 (ru) 1982-08-15
SE7810947L (sv) 1980-04-21
DD146708A5 (de) 1981-02-25
CA1131632A (fr) 1982-09-14
PT70350A (en) 1979-11-01
ATE1145T1 (de) 1982-06-15
DK148884B (da) 1985-11-04
FI793224A (fi) 1980-04-21
DK148884C (da) 1986-04-07
GR72945B (fr) 1984-01-17
IE49184B1 (en) 1985-08-21
ZA795113B (en) 1980-10-29
SG86084G (en) 1985-06-07
AU530717B2 (en) 1983-07-28
IE791987L (en) 1980-04-20
JPH0130834B2 (fr) 1989-06-22
HK7785A (en) 1985-02-08
PL119413B1 (en) 1981-12-31
NO152561C (no) 1985-10-16
DE2963021D1 (en) 1982-07-22
DK432179A (da) 1980-04-21
FI66867B (fi) 1984-08-31
JPS5557589A (en) 1980-04-28
NO793377L (no) 1980-04-22
PH16676A (en) 1983-12-13
EP0010531A1 (fr) 1980-04-30
US4548818A (en) 1985-10-22
ES485178A1 (es) 1980-05-16

Similar Documents

Publication Publication Date Title
FI66867C (fi) Foerfarande foer framstaellning av nya farmakologiskt aktiva 3-alkylxantiner
EP0011609B1 (fr) Dérivés de xanthine et préparation pharmaceutique les contenant pour utilisation dans le traitement de maladies chroniques d'obstruction des voies respiratoires et de maladies cardiaques
RU2073679C1 (ru) Производные ксантина или их фармацевтически приемлемые соли, способ получения производных ксантина или их фармацевтически приемлемых солей, фармацевтическая композиция
FI66383C (fi) Foerfarande foer framstaellning av farmakologiskt aktiva xantinderivat
US4546182A (en) 3,8-Dialkylxanthines
JPH02502732A (ja) １，３‐非対称直鎖アルキル置換８‐フェニルキサンチン化合物
DE2264374C3 (de) 4-Hydroxy-5-phenoxy-pyrimidine, Verfahren zu ihrer Herstellung und diese enthaltendes pharmazeutisches Präparat
KR830001654B1 (ko) 만성장애 기도증과 심장병 치료를 위한 3-알킬 크산틴의 제조방법
CA1142928A (fr) 3-alkylxanthines, intermediaires, procedes de preparation, composition et methodes pour le traitement de l'obstruction chronique des voies respiratoires et des maladies cardiaques
DD237660A5 (de) Verfahren zur herstellung von purinderivaten
CS221846B2 (en) Method of making the ethanolamine derivatives
JPH05262770A (ja) 化学的製法
CN1730475B (zh) 芳胺烯酮类化合物、其合成方法、含有其的药物组合物及用途
JPH11502519A (ja) 新規な１−エチル−１，２−ジヒドロ−２−オキソ−３−メチルアミノキノキサリン誘導体、それらの医薬品としての使用、およびそれらを含む医薬組成物

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: AKTIEBOLAGET DRACO